272 related articles for article (PubMed ID: 26096845)
21. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole.
Chu SW; Badar S; Morris DL; Pourgholami MH
Anticancer Res; 2009 Oct; 29(10):3791-6. PubMed ID: 19846910
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP.
Xie X; Bartholomeusz C; Ahmed AA; Kazansky A; Diao L; Baggerly KA; Hortobagyi GN; Ueno NT
Mol Cancer Ther; 2013 Jun; 12(6):1099-111. PubMed ID: 23543364
[TBL] [Abstract][Full Text] [Related]
23. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
24. Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic.
Uckun FM; Ek RO; Jan ST; Chen CL; Qazi S
Br J Haematol; 2010 May; 149(4):508-17. PubMed ID: 20151979
[TBL] [Abstract][Full Text] [Related]
25. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
26. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events.
Zeng KW; Wang S; Dong X; Jiang Y; Jin HW; Tu PF
Toxicol Appl Pharmacol; 2014 Mar; 275(3):244-56. PubMed ID: 24486434
[TBL] [Abstract][Full Text] [Related]
27. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
Pine PR; Chang B; Schoettler N; Banquerigo ML; Wang S; Lau A; Zhao F; Grossbard EB; Payan DG; Brahn E
Clin Immunol; 2007 Sep; 124(3):244-57. PubMed ID: 17537677
[TBL] [Abstract][Full Text] [Related]
28. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
[TBL] [Abstract][Full Text] [Related]
29. Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells.
Amaya C; Luo S; Baigorri J; Baucells R; Smith ER; Xu XX
BMC Cancer; 2021 Sep; 21(1):981. PubMed ID: 34470602
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS
Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076
[TBL] [Abstract][Full Text] [Related]
31. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.
Yang X; Shen J; Gao Y; Feng Y; Guan Y; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Int J Cancer; 2015 Oct; 137(8):2029-39. PubMed ID: 25904021
[TBL] [Abstract][Full Text] [Related]
32. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
Coley HM; Shotton CF; Ajose-Adeogun A; Modjtahedi H; Thomas H
Biochem Pharmacol; 2006 Oct; 72(8):941-8. PubMed ID: 16934227
[TBL] [Abstract][Full Text] [Related]
33. Comment on "Therapeutic targeting of Syk in autoimmune diabetes".
Kapoor S
J Immunol; 2011 Feb; 186(4):1885; author reply 1886-5. PubMed ID: 21289311
[No Abstract] [Full Text] [Related]
34. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.
Boros K; Puissant A; Back M; Alexe G; Bassil CF; Sinha P; Tholouli E; Stegmaier K; Byers RJ; Rodig SJ
Oncotarget; 2015 Sep; 6(28):25575-87. PubMed ID: 26315286
[TBL] [Abstract][Full Text] [Related]
35. Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
Broggini-Tenzer A; Sharma A; Nytko KJ; Bender S; Vuong V; Orlowski K; Hug D; O'Reilly T; Pruschy M
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25694444
[TBL] [Abstract][Full Text] [Related]
36. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
Uckun FM; Qazi S
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
[TBL] [Abstract][Full Text] [Related]
37. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
[TBL] [Abstract][Full Text] [Related]
38. SYK is a candidate kinase target for the treatment of advanced prostate cancer.
Ghotra VP; He S; van der Horst G; Nijhoff S; de Bont H; Lekkerkerker A; Janssen R; Jenster G; van Leenders GJ; Hoogland AM; Verhoef EI; Baranski Z; Xiong J; van de Water B; van der Pluijm G; Snaar-Jagalska BE; Danen EH
Cancer Res; 2015 Jan; 75(1):230-40. PubMed ID: 25388286
[TBL] [Abstract][Full Text] [Related]
39. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
[TBL] [Abstract][Full Text] [Related]
40. Development of a pharmacodynamic assay based on PLCĪ³2 phosphorylation for quantifying spleen tyrosine kinase (SYK)-Bruton's tyrosine kinase (BTK) signaling.
Hsu J; Zhang J; Kitson C; Tan SL; Narula S; DeMartino JA; Liao C
J Biomol Screen; 2013 Sep; 18(8):890-8. PubMed ID: 23704133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
